



**THE UROLOGY FOUNDATION**  
**TRUSTEES' ANNUAL REPORT & FINANCIAL STATEMENTS**  
**DECEMBER 2021**



## Contents

Chairman's statement .....	3
Overview of the year .....	3
Objectives and Activities .....	4
Our Vision and Mission .....	4
Our Aims .....	4
Our Values .....	4
What we do .....	4
Public Benefit .....	5
Grants policy .....	5
Comparison of 2020 v 2021 .....	6
Achievements and Performance in 2021 .....	7
1. Seeking better treatments and cures through research .....	7
2. Improving knowledge and skills through training .....	9
3. Improve public awareness of urological conditions and symptoms .....	10
4. Plans for the future .....	11
Financial Review .....	12
Financial Results of Activities & Events .....	12
Fundraising .....	12
Reserves & Liquidity Policy .....	12
Statement of going concern .....	13
Investments Policy .....	13
Remuneration policy .....	13
Pensions policy .....	13
Equal opportunities and diversity policy .....	13
Principal risks and uncertainties .....	14
Structure, Governance & Management .....	16
Charity Governance Code .....	16
Trustee Recruitment, Training and Induction .....	16
Appointment & Election .....	16
Relationships with Related Parties .....	17
Representation on Other Bodies .....	17
Reference and administrative details .....	18
Trustees .....	18
Registered Office .....	18
Auditors .....	18
Trustees' & Directors' Responsibilities in the Preparation of Financial Statements .....	19
Auditor .....	19
Statement as to disclosure of information to the auditor .....	19
Annex A .....	20

Front cover image courtesy Findlay MacAskill, urology trainee, completing the Hackney Half Marathon for TUF.






## Chairman's statement

### Overview of the year

It was pleasing to see the charity able to make more awards and to support more urologists and researchers in 2021, compared with the previous year, in spite of the continuing impact of Covid-19 on our operations. We are currently funding over 50 projects covering a range of urological diseases from prostate, kidney and bladder cancer to urinary tract infections and incontinence. This was largely due to our regular donors, and to Trusts & Foundations and companies, many of whom share our mission of improving quality of life and outcomes and saving lives. Without their ongoing commitment and support our ability to make awards, meet our objectives and support the urology community would have been more limited, particularly as opportunities to fundraise were still constrained due to Covid-19.



2021 saw The Urology Foundation making some significant investment into urological research and care, most notably the creation of our TUF Trials Unit. Following a competitive tendering process we signed a three year partnership with the Centre for Healthcare Randomised Trials centre in Aberdeen to encourage and enable more clinical research in urology. Trials are an important way of measuring a medical, surgical or behavioural intervention and successful trials are catalysts for change, provide potential for transformational discoveries and drive improvements in services. The role of the TUF Trials Unit is to identify promising and important research ideas from urology departments from all corners of the UK and provide a team of medical investigators to bring those ideas to fruition. This approach will enable more high-quality urology trials to take place, leading to better care, quicker recovery times and fewer long-term issues.

2021 also presaged some changes to the TUF team with our Chief Executive, Louise de Winter, saying she wished to step back into a part time role within the organization. We are hugely indebted to Louise for her leadership and commitment to TUF over the past decade. Since her tenure TUF has expanded its programmes and funding to provide many more opportunities for research and training, and also to include specific funding for urology nurses. So, we were thoroughly delighted that Louise expressed her wish to continue to contribute to TUF in a renewed capacity as Director of Research & Operations, as she remains deeply committed to the charity and looks forward to being a part of its ongoing future success.

We were very pleased to welcome Rebecca Porta as our new TUF CEO in January 2022. Rebecca has held senior roles within some of the UK's leading health and medical research charities, and was Chief Executive of Orchid Cancer Appeal, the male cancer charity for over 11 years, responsible for driving transformation and growth including the introduction of Nurse-led Services, training for healthcare professionals and national media campaigns. We are confident she will build upon the excellent work and foundations that Louise has created and help us take The Urology Foundation to the next level.

Finally, it was a pleasure to connect in person with some of our donors and supporters at the TUF dinner hosted by TUF Patron, Jane MacQuitty at Vintners' Hall last November. It provided a real boost to morale and a fantastic evening was had by all, with more funds raised to support our vital work. We will continue to put the needs of urology patients and the urology community of professionals at the heart of what we do.

A handwritten signature in black ink, appearing to read 'P. Fletcher', written over a light blue horizontal line.

Paul Fletcher, Chairman



## Objectives and Activities

The Urology Foundation's objects are to:

“Advance, promote, encourage, develop and improve the study and knowledge of urology, urological surgery and the general knowledge of science and medicine and all matters relating to the progress and development of that branch of science and medicine and for that purpose to fund, aid, maintain and endow scholarships, fellowships, chairs and bursaries and generally to assist in the funding, instruction and support of persons and institutions engaged or involved in urological research work.”

### Our Vision and Mission

We see a world where people will not die early from urological cancers and diseases, and where people with bladder, kidney and prostate problems can still lead full, active and productive lives.

Our mission is to improve survival and quality of life for urology patients through research and training, so patients receive the best possible treatment and care and fewer lives are devastated.

### Our Aims

The Urology Foundation is committed to reducing the suffering caused by urological diseases. We work with researchers, urology and health care professionals to improve the diagnosis, treatment and management of urological disease and the nation's urology care.

We rely on donations from individuals, trusts and foundations, and from companies to help fund our work. The money we raise is invested directly into research to find better treatments and cures, and in training for urology professionals to care for and help people affected by urology conditions.

The Foundation is governed by the rules and regulations set down in its company memorandum and articles of association originally dated 12 February 2009 and last updated by a special resolution on 29 June 2009.

### Our Values

In undertaking our remit we are:

- *Ambitious* to see UK urology care, treatment and practice is the best in the world.
- *Dedicated* to beating all urology diseases through research and training.
- *Proud* of working in urology and committed to transforming the lives of people with a urology condition.
- *Collaborative*; working with researchers, urologists, nurses and health care professionals, influencers and decision makers, other charities, patients and their families we are improving the nation's urology care.

### What we do

We seek to improve patient treatment and care through investing in research and training. We fund research that increases our understanding of urological diseases and that can bring about change in urology practice and guidelines to the benefit of patients. We are also looking for ways that can make treatments more effective and kinder. We are driving improvement in standards in urology practice through training and we are developing the next generation of urological experts who can meet the challenge of the increased burden of disease and who put excellence of care at their core.

Our website provides information on the signs and symptoms of urological diseases and sets out some of the treatment options available. Our campaigns such as Urology Awareness Month in September bring urology conditions to the public eye, and focus on breaking the stigma of these diseases.





## Public Benefit

The trustees have taken The Charity Commission's general guidance on public benefit into consideration in preparing their statements on public benefit contained within this trustees' annual report. In accordance with its charitable objectives, The Foundation gives grants to individuals and not-for-profit organisations to:

- Promote the study of urological cancers and conditions by supporting and carrying out research into the causes, prevention, diagnosis and method of treatment of this disease and by publishing the useful results of such research;
- Provide opportunities for training and education of health professionals working in urology, in order to advance practice and improve patient treatment and care;
- Such other purposes for the benefit of the community as shall be exclusively charitable as the trustees from time to time shall decide.

In addition, TUF provides information on its website on urological cancers and conditions, and raises awareness through social media channels and media such as press and radio.


## Grants policy

TUF advertises its programmes and awards on its website and through its professional e-newsletter. Applications for Research Scholarship funding are assessed by the SEC and the Reviewing Panel. Other applications for funding are assessed by the SEC.

TUF is a member of the Association of Medical Research Charities (AMRC) and abides by its standards and guidelines for peer review and funding. It is also a National Institute for Health Research (NIHR) non-commercial Partner. Research studies funded through TUF's NIHR approved funding streams are automatically eligible for consideration for NIHR Clinical Research Network (CRN) support subject to meeting the standard study eligibility criteria.



## Comparison of 2020 v 2021 An Overview







# Achievements and Performance in 2021

## 1. Seeking better treatments and cures through research

With over 750,000 urology hospital care episodes each year in the UK, urology is a specialty faced with a high demand, yet the field remains remarkably under researched. While there have been notable successes in prostate cancer, much of urological practice lacks level one evidence to guide practice. Surgery in general, and urology in particular, currently attracts a disproportionately small proportion of clinical trials funding compared with the massive burden of urological diseases on NHS expenditure. Two key factors that have led to lack of trials are the complexity of surgical trials and the potentially hazardous and invasive nature of interventions.

We set out to address these challenges by creating an infrastructure to develop fund worthy urological trials by securing sufficient methodological expertise and support for good research ideas. Successful trials that go on to develop evidence for best practice and guidance on treatment of urological diseases will result in huge patient benefits. Our competitive call to work with an established Trials unit within the UK attracted responses from one third of all the units throughout the UK, leading us to set up the TUF Trials Unit in partnership with the Centre for Healthcare Randomised Trials (CHaRT) in Aberdeen.

**TUF Trials Unit (TTU):** in 2021 following a Dragon's Den session to consider ideas for urological trials, two proposals have been taken forward by the TTU:

 <p><b>Urology trainee, Nikita Bhatt, wants to investigate the use of stents following stone surgery.</b> Patients undergoing uncomplicated telescopic stone surgery routinely have a stent placed after their operation in majority of the cases, despite guidelines stating these may not be necessary.</p> <p>Stents have a role in some cases but patients usually find them bothersome, interfering with their daily activities and affecting their quality of life. In some cases they can cause harm.</p> <p>No previous trial has compared patients' quality of life with or without a stent after such a procedure, we hence want to find out if there is a difference in this that may change clinical practice.</p>	<p><b>Consultant urologist, Krishna Narahari, wants to assess the clinical and cost effectiveness of pelvic lymph node dissection (PLND) in high-risk prostate cancer surgery.</b></p> <p>The role of PLND in prostate cancer surgery has been controversial for the last 3 decades. Perceived benefits include optimal staging, identifying candidates for additional therapies and possible better cancer control. Harms include higher op time and complications such as blood loss, lymph collections requiring interventions and injury to nerves and vessels. To date, there remains a distinct lack of evidence of benefit of PLND in prostate cancer.</p> <p>The purpose of this clinically integrated pragmatic randomised multicentre UK trial is to address this evidence gap and inform surgical practice worldwide.</p> 
---	--

2021 also saw the introduction of our new funding stream, the **Innovation & Research Award**, replacing our previous Research Scholarships. The award funds projects up to a value of £60,000 that seek to use new, exciting, innovative approaches to address urological diseases and disorders. The projects must either (a) aim to create innovative treatments or devices, (b) aim to deliver innovative care pathways or (c) aim to use innovative research techniques or methods. It was gratifying that in its first year, the award attracted a high number of applications (19) from across the UK and a wide range of urological conditions.

Five projects were selected for funding:

**Kidney tumours:** There are approximately 13,000 new kidney cancer diagnoses in the UK each year, projected to rise by 26% by 2035. Due to increasing use of medical imaging, most kidney tumours are





now detected incidentally at an early stage i.e. picked up on a scan done for another reason. However, not all lumps that grow in the kidney are cancer. As many as two in every ten growths found in the kidney incidentally are a non-cancerous. This project aims to evaluate existing and novel diagnostic imaging techniques in the assessment of small renal tumours, with a view to reducing unnecessary invasive diagnostics and management in patients with benign disease.

**Kidney stones:** Kidney stone disease is a common problem that affects ~20% of men and ~10% of women by 70 years of age. Unfortunately, up to 50% of individuals who have formed a kidney stone will form a second stone within 10 years of their first. Furthermore, individuals who recurrently form kidney stones are at increased risk of chronic kidney disease. The reasons why some people form kidney stones recurrently are poorly understood and the need for improved treatments is widely recognised. This project aims to understand associated genetic variants and identify drugs that have the potential to be innovative therapies for kidney stone prevention.

**Bladder Cancer:** Bladder cancer (BC) is the seventh most common cancer in the UK and is associated with increasing age and smoking. As the population ages rates of incidence will likely increase. The current gold standard for diagnosing BC is cystoscopy under local anaesthesia but this invasive procedure is associated with complications. This study will look at alternative ways of diagnosing BC through electrical analysis of cells in urine, and identify methods of tumour grading, ahead of a subsequent clinical trial.

**Incontinence:** The prevalence of Stress Urinary Incontinence (SUI) in women aged over 21 years in the UK has been reported to be 24%, with 9% of those considering it bothersome enough to want surgical treatment. This project aims to develop and validate a system that can be used to measure pressure along the urethra (waterpipe/bladder outlet) during surgery to treat stress urinary incontinence (SUI, leakage of urine during exercise, cough, sneeze or strain).

**Pelvic Mesh implants:** In pelvic mesh surgery, a sheet of material is permanently implanted to support pelvic organs that have shifted downwards into the vagina, or to treat the involuntary leaking of urine. Research suggests up to 30% of women experience long-lasting pelvic pain after pelvic mesh surgery. However, the current tools used to assess pain related to pelvic mesh implants have not been developed specifically for these patients. Therefore, our current understanding of the problem might be incomplete. To address this issue, the aim of this project is to develop a questionnaire that can be used to assess pain associated with pelvic mesh implants. In particular, the questionnaire could be used to assess outcomes following mesh removal procedures.

In 2021 our **Small Research Projects fund**, which is geared towards improving treatment and care, once again received a high level of applications in the first round (11). We had increased our budget for these awards in 2021 to accommodate four projects. The variety and quality of the applications were such that we were able to make all four awards from this tranche but sadly had to close the fund for the rest of the year. Awards were for the following projects:

- Accurate and timely detection of testicular torsion by urology registrars in training.
- A pilot study into measuring urine flow remotely, to speed up diagnostic appointments and reduce waiting times.
- Research into BXO, a chronic and progressive inflammatory skin disease affecting the male external genitalia, causing deformities and considerable pain.
- Developing new measures for reporting male infertility trials, to ensure better treatments going forward.

In addition to the above grants and awards, we were also fortunate to receive funding from The Champniss Foundation and the Champniss Charitable Trust to fund a **Cancer biomarker / wearable sensor study**, to establish and test a repository for integrating genomic and wearable sensor data in order to explore a relation between the two and cancer outcomes. This study is being led by Professor John Kelly at University College London (see box).





## Case study: Seeking better treatments and cures through research

### *Collecting and integrating genomic and wearable sensor data in order to explore a relation between the two and cancer outcomes.*

Covid-19 has highlighted the need to be able to track post-operative cancer patients remotely for any signs of degradation in health or recurrence of cancer. Moving forwards, there will also be a desire to reduce unnecessary hospital appointments for the patient, if remote monitoring is effective and reliable.

There is a correlation between a patient's physical activity and recurrence of cancer. Loss of activity is strongly associated with cancer specific survival in patients after radical cystectomy. An initial study in post-operative cancer patients wearing fitness trackers (eg Fitbits or similar) showed that loss of activity was detected *prior to evidence of measurable disease on imaging*, and suggests that there may be changes in activity at a very early stage of cancer recurrence. We now wish to combine this data with genomic changes in patients' blood samples for evidence of cancer recurrence.

Taken together, the combined approach may well reveal markers for clinically relevant states such as disease recurrence and progression. Further, linkage between the genomic state and the activity state may highlight cases for additional therapies, and be a means to monitor response to therapy.

## 2. Improving knowledge and skills through training

The impact of the pandemic on formal training continued during 2021 while the NHS struggled to cope with backlogs and staff shortages. Nevertheless, we launched our TUF/Urolink Fellowships which provide UK trainees opportunities to teach and train in low to middle income countries, and saw a take up in applications for trainees to supplement their training.

### **Support for urology trainees**

The **TUF/Urolink Fellowships** is open to those senior level trainees who have completed their FRCS (Urol) and it is expected that the successful applicants will accompany established workshop teams in the first instance, and stay to work in that centre (or those centres) for an unspecified time after the workshop team's departure. In 2021 three awards were made:

- Nishant Bedi from Barts Health NHS Trust
- Patrick Gordon from St James Hospital Leeds
- Su-Min Lee from Musgrove Park Hospital, Taunton

The destinations for each of the visits are still to be advised, and we hope they can take place in 2022.

The **Keith Yeates Medal/Ralph Shackman** prize is only conferred when candidates achieve over 90% in their Intercollegiate Specialty Examination in Urology. In 2021 two candidates made the grade: Ms Sophia Cashman and Mr Ben Starmer. They each receive a travelling fellowship worth £2,000. Due to ongoing travel restrictions at the time, they have yet to arrange their visits.

### **Support for urology nurses**

Our planned **Communications and Leadership Skills** course for nurses, originally planned for 2020, had to be postponed yet again because of the pandemic. A date has now been set for 2022. Sadly, because of the ongoing pandemic and restrictions around travel, there were no applications for TUF travel grants for nurses in 2021. We hope this funding stream will pick up in 2022. TUF is liaising with




representatives of the British Association of Urological Nurses (BAUN) to support ongoing nurse training and education.

### 3. Improve public awareness of urological conditions and symptoms

The Urology Foundation has continued to build public awareness of urological cancers and conditions as well as raise the profile of urologists and urology nurses for better patient care. Our main channel for engaging with the public has been through our website, with visitor numbers spiking during Incontinence Week in June and during September Urology Awareness Month. The most visited pages continue to be those that provide health information on the male reproductive organs, Urinary Tract Infections (UTIs), kidney stones and bladder problems. The majority of website visitors are women (52%) but the highest number of users were in the 18 - 34 age range, comprising 44% of visitors to the site.

TUF's social media profile is also growing with Facebook and Instagram more popular among the general public. Our Facebook user numbers have historically risen most around World Continence Week in June and Urology Awareness Month in September. Twitter and Linked-In have higher numbers of urology professionals engaging. During 2021, our Twitter followers increased by 10 per cent bringing the total number of followers to 4,436. The average numbers of people seeing each tweet is just shy of 1,200.

Our Urology Awareness Month in September focused on the need for people to be open about concerns and to get checked if worried about any symptoms; provided key information on signs to look out for and tips and advice for maintaining good urological health (examples below). We featured in key press such as the *Journal of Clinical Nursing*, and a Guardian Media Planet supplement, as well as providing content for online health forums and lifestyle websites such as *ManDad Magazine*.



We continued to partner with TalkHealth, an online health website, to provide information blogs and expert-led medical advice forums about urological health matters to members of the public, and to provide articles on urological health matters for supplements in national newspapers.





#### 4. Plans for the future

The incidence of urological cancers and conditions is increasing, as is the prevalence of bladder and incontinence problems, benign prostate problems and kidney stones. This is leading to major morbidity and quality of life issues for urology patients and places a growing burden on the healthcare service, and on those working within it. Allied to this, the way in which healthcare is delivered will need to change, with an emphasis on personalised medicine and community-based services which are designed to enhance both patient outcomes and experience.

In 2021 we introduced two major new grant programmes, the TUF Trials Unit and our Innovation & Research Awards, and we were gratified to see such a positive response and so many applicants to these. We aim to ensure that more urology professionals from around the UK regions can benefit from the opportunities we offer, and we intend to create some regionally specific awards to facilitate access to our programmes.

In May 2021 our CEO, Louise de Winter, announced her intention to stand down and move to a part time role within the charity. She now has responsibility for our programmes and grants, and has plans for introducing a new system to make it easier for people to apply online for grants and for peer reviewers to comment. With over 50 active open grants, TUF needs a robust system for managing our grants and grant holders, and for keeping track of where the research we have sponsored leads.

Rebecca Porta joined the charity as CEO on 4 January 2022. Her appointment provides us with an opportunity to revisit our strategic goals and to ensure our programmes and activities align with the needs of urology patients and urology community. A key focus will be to ensure that going forward, we work with a wide range of stakeholders to drive change and improve the outlook for those affected by or interested in urology.


Given the impact of the pandemic we will look to diversify our income streams - this will include expanding our events programme, developing partnerships with the wider business community alongside strengthening existing relationships and investing in our marketing and communications programme. To this end there are plans to hold a strategy session in early 2022.

The key to meeting the many challenges of urological disease is to develop a cadre of top-quality urological professionals who have access to the very latest research developments and technological innovations, and who put excellence of care and continuous professional development at their core. We will develop research and training programmes with these outcomes, and the wellbeing and quality of life of patients, in mind.



## Financial Review

### Financial Results of Activities & Events



The total value of net assets held by The Urology Foundation on 31 December 2021 was £2,447,884 (2020 £2,158,423). The Foundation's fundraising activities and other initiatives during the course of 2021 generated a total of £686,522 of voluntary income (2020 £1,366,619) and a further £83,389 (2020 £64,920) from specific fundraising event income.

### Fundraising

TUF continues to be wholly reliant on fundraised and donated income to fulfil its remit. The charity operates a mix of its own fundraising activities and those organised and undertaken by third parties on its behalf.

The ongoing uncertainty of Covid-19 continued to impact our fundraising, with our charity trek to Machu Picchu having to be postponed once again. However, our annual Bike4TUF cycle ride took place with a 250 mile ride through the north Cotswolds and Warwickshire, raising over £30,000. We are also grateful to a number of individual patients, supporters, urologists and trainees who undertook various fundraising challenges for TUF, raising over £7,800.

In November we were fortunate to be able to finally go ahead with our Wine Tasting Dinner and auction at Vintners' Hall, with TUF Patron and *The Times* Wine Correspondent, Jane MacQuitty, as our host and guide to the wines. The evening raised £45,000 and it was clear that there was a real joy among guests at being able to be together in a room, rather than on a zoom screen.

However, once again a huge and special thanks must be paid to TUF's ongoing supporters who donated throughout the year. The Foundation also received a number of significant donations from Trusts and Foundations and individuals, which did so much to enable our programmes and operations to continue throughout this difficult year. (See Annex A.)

### Reserves & Liquidity Policy

The Foundation currently has 'free reserves' of £2,097,116 (31 December 2020: £1,675,542).

The Foundation's policy is to maintain reserves sufficient to continue to fund its objectives on a long term basis, and to ensure that TUF operates with an adequate level of liquidity to (i) minimise the risk associated with a temporary or unforeseen shortfall in liquidity; (ii) manage its cash and





investments to meet its liabilities and remain a going concern for at least 1 year in the event of an unplanned drop in income. Liquidity is defined as cash and the investment portfolio held as Unrestricted funds. The Policy establishes a minimum liquidity target for TUF of £500,000 (“Minimum Required Reserve”) subject to future modification by the Finance Committee and trustees’ approval.

The trustees consider that reserves held in excess of the amounts required to fund all future commitments together with the initial fund of £500,000, will be available to increase its visibility and expand its operations including funding for further research and a wider range of projects. The trustees plan levels of expenditure from unrestricted and restricted funds for the year ahead based upon the level of incoming resources for the current year as well as utilising restricted funds.

### Statement of going concern

The Foundation’s unrestricted net funds generated in 2021 are judged to be sufficient to meet the requirements of the charity for charitable giving in the coming year.

### Investments Policy

The Foundation’s investments are managed by Rothschild Bank (CI) Limited. The Treasurer and the Chief Executive are responsible for managing the relationship with Rothschild but changes in investment strategy are subject to approval by the board of trustees. The investment manager is asked to attend at least one board meeting annually.

The board follows a medium risk ‘Balanced’ investment strategy which is intended to achieve steady growth over the long term through a diversified approach to investment. Capital preservation in real terms over a long term horizon is the primary objective and some volatility is acceptable in order to achieve this. TUF’s investments are held in the Exbury Fund, an ethical portfolio managed by Rothschild. The fund achieved a 14.5% return over 2021.

All other Foundation funds are held in accounts with the charity’s bankers, National Westminster Bank plc. In 2021 the charity closed its account with CCLA Investment Management Limited, and the balance of funds (c. £11,000) were transferred to the charity’s NatWest bank account.

### Remuneration policy

In setting salary levels, The Urology Foundation follows the National Council for Voluntary Organisation’s advice that a charity’s pay policy should be to offer fair pay to attract and keep appropriately-qualified staff to lead, manage, support and/or deliver the charity’s aims. It also conducts online research of charity salaries and uses surveys to benchmark levels of pay. The Urology Foundation does not automatically award its staff with annual salary increases, either incremental or cost of living.

### Pensions policy

The charity offers a stakeholder pension, operated by The People’s Pension (B&CE Holdings), in line with statutory requirements. All new staff are automatically enrolled but can opt out if desired.

### Equal opportunities and diversity policy

TUF is committed to being an Equal Opportunities employer and to respecting diversity, and is determined to ensure that no job applicant, employee, or trustee receives less favourable treatment on the grounds of their age, disability, gender reassignment, marriage and civil partnership, pregnancy or maternity, race, religion or belief, sex or sexual orientation. TUF also seeks to ensure that its employees are not victimised or subjected to harassment.

The policy applies to recruitment and selection for jobs in the Foundation, career development and training, promotion and transfer, performance management, pay, redundancy, disciplinary and grievance procedures, the application of terms and conditions of employment and any other aspects of employment with the Foundation.



The policy also applies to third parties such as trustees and committee volunteers, clients (ie grant applicants) and suppliers.

## Principal risks and uncertainties

The trustees take the management of risks seriously. The Chairman of the board of trustees and the Chief Executive are charged with responsibility to ensure that the risks which have been identified are adequately assessed and properly mitigated on a regular basis. The potential risks have been discussed with the Chairman and the charity and a formal risk register is kept and brought before the board on at least an annual basis.

### *Impact of Covid-19 and war in Ukraine*

The pandemic continued to affect the urology workforce, which meant that applications to some of our programmes - mainly travel and fellowship grants - remained low. However, our applications for research grants were not impacted, and we also saw some pickup in activity with researchers returning to labs. Looking forward, the ongoing war in Ukraine has broader economic implications, some of which will be reflected in our investment fund holdings. Our Investment Manager keeps us regularly updated and there is no immediate cause for concern or action.

### *Risks to Data*

The charity takes its responsibilities for data very seriously. We follow a Data Protection policy based on the GDPR and have a nominated trustee (Mr Adrian Joyce) who has Board oversight for data compliance. We use a professional data base provider that stores all information in the cloud and this is secured using a two-step password verification. We review our records on an ongoing basis and delete old or historical records that are no longer relevant, and remove people who no longer wish to hear from us (provided that there is no financial information that we need to retain).

Other key risks are assessed as follows:

Governance /Environmental	Impact of the external environment on fundraising, in particular: public confidence in charities; new fundraising regulations; Data Protection Regulations.
Income Sources	TUF is wholly reliant upon voluntary income as an annual source of funding. It is the role of the trustees to manage risk exposure on fundraising activities and in doing so to accept an appropriate level of risk in order to raise income from a wide range of sources.
Risk of data breach	The charity uses a professional database provider that stores all information in the cloud and this is secured using a two-step password verification. TUF also regularly deletes any old or historical records that are no longer relevant. The charity's own day to day working documents are also stored on a cloud-based system. We believe that keeping data in the cloud is still safer than keeping it on our own servers. TUF staff are regularly made aware of possible phishing scams and to be alert to any potential email or system data breaches.
Key Person risk	The small staff base makes TUF heavily reliant on the Chief Executive and a few key trustees so the unexpected loss or departure of the Chief Executive or certain trustees is a risk. Succession planning processes have been identified as necessary going forward.
Investment Risk	TUF's success is directly related to the amount of resource it can devote to its objectives, so the key risk identified by trustees relates to the proper management of its funds. Imprudent or unprofessional decisions could majorly impact on the performance of those funds. In common with similar charities, TUF employs professional fund managers, whose performance is regularly reviewed by the Treasurer together with other trustees.
Risk to Employees	Employees are not subject to risks other than those likely to be associated with routine office work. Apart from obtaining statutory Employers Liability





	Insurance, TUF nonetheless treats the welfare of its staff as a priority. The Chief Executive is the Nominated Safety Officer for the purposes of the Health and Safety at Work Act. The premises are checked and maintained by the landlord and by the fire service to ensure appropriate mitigation of the risk of fire. Employees are aware of the location of fire extinguishers. The charity also has a number of policies in place covering Equal Opportunities, Lone Working, Working from Home and Safe Guarding Vulnerable People.
Risk that research fails to deliver results	Grants awarded are subject to rigorous review by the SEC and Reviewing Committee. Grantees are expected to submit progress reports and these are reviewed by the SEC and TUF. The charity maintains ongoing communication with grant holders.
Loss of Records	To protect against the loss of records, and to increase data security, files are stored in the cloud. The risk of any unsaved data being critical to TUF is regarded as insignificant. Other similar risks are dealt with by insurance.



## Structure, Governance & Management

The Urology Foundation is a charity and a company limited by guarantee and was established on 12 February 2009 to incorporate the charitable activities of the British Urological Foundation (BUF), an unincorporated charitable trust established in 1994 by the British Association of Urological Surgeons and BJU International, and a registered charity since 17 March 1995. The Urology Foundation itself became a registered charity on 19 March 2009.

### Charity Governance Code

The Board and Executive of the charity abide by the standards set by the Charity Governance Code when executing their duties. The overall strategic direction of the charity is determined by the trustees, who meet three times each year including an Annual General Meeting.

### Trustee Recruitment, Training and Induction

The Foundation seeks to achieve a balance of lay and medical trustees. Appointed trustees are recruited on the basis of fulfilling the criteria to provide a balance of experience and knowledge. Members of the charity's Scientific and Education Committee (see below) are recruited through calls in industry publications.

All new trustees are provided with a face-to-face induction meeting and an induction pack. They are provided with relevant Charity Commission publications and regularly briefed on developments and opportunities that will support their general understanding of the voluntary sector, healthcare and medical research issues.

### Appointment & Election

The Trustees and Chairman are appointed for an initial period of three years that can be extended for a further three-year term. A further extension may be made if it is deemed to be in the best interests of the Charity. The governing document requires that there should be a minimum of seven trustees.

Two of the trustees are required to be representative trustees, one nominated by The British Association of Urological Surgeons ("BAUS") and one nominated by British Journal of Urology International ("BJUI"). All other trustees, known as appointed trustees, are appointed by unanimous written resolution of all the trustees present and/or voting at a special meeting of trustees called to take place immediately before or after an ordinary meeting of trustees.

The representative trustee nominated by BAUS is the President of BAUS and his appointment to the board is concurrent with his post at BAUS, which is for a period of two years.

### *The Executive Team*

The Chief Executive, is responsible for the day-to-day management of the charity. She is assisted by a Director of Research & Operations and a Fundraising & Events Manager.

The Chief Executive deals with the implementation of policy and strategic decisions taken by the board of trustees. She and the appropriate staff members attend the meetings of the board of trustees and of all sub-committees, and report on the day-to-day operations of the charity. The Foundation currently operates the following sub-committees:

### *Scientific and Education Committee (SEC)*

The SEC is responsible for the development and assessment of The Foundation's research, education and training programmes and the review and administration of The Foundation's grant making policy. The Chairman of the SEC, Professor Grant Stewart, is a member of the board of trustees, and reports back to the board on the work of the Committee. The SEC is made up of clinical and academic urologists and scientists with an interest in urology, and lay representatives. The BAUS Surgical





Specialty Lead also sits on the SEC, *ex officio*, to provide further insight into the research and training needs of the profession.

### **Research Scholarship Review Panel**

The Research Scholarship Review Panel is responsible for assessing applications for TUF's major research grants and marking these according to the requisite criteria being met. In this task it assists the SEC in its final decision on who should receive grants. The Research Scholarship Review Panel is made up of clinical trustees and academic urologists and scientists with an interest in urology.

Membership of the SEC and Review Panel can be viewed on the charity's website: <https://www.theurologyfoundation.org/about-us/who-we-are/our-team/committees>. They provide their services as volunteers and TUF is enormously grateful to them.

### **Finance Committee**

The charity Finance Committee is chaired by the Treasurer, Ms Angela Daniel. Membership includes The Chairman of the Board and the Chairman of the SEC, and two other trustees: Mr Becker & Mr Nicol, the Chief Executive and the Director of Research & Operations. Any recommendations made by the Finance Committee are brought to the board of trustees for discussion and ratification. The Treasurer has oversight of the charity's bank and investment accounts.

### **Relationships with Related Parties**

The Urology Foundation continues to maintain close links with its two founding charities, The British Association of Urological Surgeons (BAUS) and the BJU International, whose representatives are trustees. TUF is also represented on BAUS Council by trustee, Mr Ben Challacombe.

### **Representation on Other Bodies**

The charity is a member of the Association of Medical Research Charities (AMRC), which confers a quality mark for TUF's peer review processes, as well as advocating for charity-funded research with government. The Urology Foundation is a National Institute for Health Research (NIHR) non-commercial Partner. This means the studies that we fund may be eligible to access the NIHR Study Support Service which is provided by the NIHR Clinical Research Network. In 2022, TUF became a member of Cancer 52, a collaborative voice for rare and less common cancers and a member of the National Council for Voluntary Organisations.



## Reference and administrative details

The registered charity name is “The Urology Foundation” (sometimes referred to as “TUF”), a charity and a company limited by guarantee.

### Trustees

Mr Paul Fletcher (*Chair*)  
Ms Angela Daniel (*Treasurer*)  
Mr Mark Becker (*Secretary*)  
Prof Grant Stewart (*Chair, SEC*)  
Mr Ben Challacombe  
Ms Mary Garthwaite  
Mr Adrian Joyce  
Prof Alan McNeill (*BJUI rep, appt Feb 2022*)  
Mr Roland Morley  
Mr David Nicol  
Mr Tim O’Brien (*BAUS rep*)  
Prof Krishna Sethia (*BJUI rep, ret'd Oct 2021*)  
Ms Hannah Warren

### President

Prof Roger Kirby

### Patrons

Mr Handel Evans  
Sir Ranulph Fiennes OBE  
Mrs Rosemary Macaire  
Ms Jane Macquitty MBE  
Mr Steven Norris

### Ambassadors

Mr Alex Corbisiero  
Mr Stephen Fry  
Mrs Kate Holmes

### Chief Executive

Ms Rebecca Porta (*appt 4 January 2022*)

### Registered Office

1-2 St Andrew’s Hill  
London  
EC4V 5BY

### Charity number

1128683 (England & Wales)

### Company number

06817868

### Auditors

Dunkley & Co Ltd  
Woodlands Grange, Woodlands Lane  
Bradley Stoke  
Bristol BS32 4JY

### Bankers

National Westminster Bank plc  
PO Box 2021  
10 Marylebone High Street  
London W1A 1FH

### Investment Manager

Rothschild Bank (CI) Limited  
St. Julian’s Court, St. Julian’s Avenue  
St. Peter Port  
Guernsey GY1 3UA





## Trustees' & Directors' Responsibilities in the Preparation of Financial Statements

The trustees (who are also the directors of The Urology Foundation for the purposes of company law) are responsible for preparing the trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company as at the balance sheet date, and of the incoming resources and application of resources, including income and expenditure, for that period. In preparing those financial statements, the trustees and directors are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records, which disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with Companies Acts 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from the legislation in other jurisdictions.

### Auditor

Mr Matthew Dobbins (FCA), of Dunkley & Co Ltd. has agreed to act as Auditor.

### Statement as to disclosure of information to the auditor

The trustees and directors at the date of approval of this trustees' annual report confirm that so far as each of them is aware, there is no relevant information of which the charity's auditor is unaware, and the trustees and directors have taken all steps that they ought to have taken to make themselves aware of any relevant information and to establish that the auditor is aware of that information.

  
Paul Fletcher (Sep 20, 2022 12:36 GMT+1)

Paul Fletcher, Chairman

Date: Sep 20, 2022



## Annex A

The Urology Foundation is extremely grateful to the following Trusts & Foundations and organisations who kindly supported our work in 2021:

Amelia Chadwick Trust  
Arbuthnott Charitable Trust  
Berni Charitable Trust  
Charles Reynolds Fund  
Dennis Byrne Charitable Trust  
Florence Shute Millennium Trust  
Girdlers' Company  
Heathside Charitable Trust  
Hudson Charitable Trust  
Irving Memorial Trust  
Lord Belstead Charitable Trust  
Masonic Charitable Foundation  
Penguins Against Cancer  
Peter Stebbings Charitable Trust  
PF Charitable Trust  
Sidney Jason Charitable Trust  
The Hadley Trust  
The Manet Trust  
The Rosetrees Trust  
The Thompson Family Charitable Trust  
Yardley SBH Trust

We are also grateful to the following companies and their staff who donated in 2020:

Bank of England Court Award  
CJ Medical  
Ginmeister Ltd  
Intuitive Surgical  
Pelicans Manufacturing Co Ltd  
Santander  
Solutions PT  
WPA Health  
Yandell Publishing

*Thank you to all our donors, fundraisers, supporters and volunteers who have made The Urology Foundation's work possible.*





**Report of the Independent Auditors to the Trustees of  
The Urology Foundation (Registered number: 06817868)**

**Opinion**

We have audited the financial statements of The Urology Foundation (the 'charitable company') for the year ended 31 December 2021 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2021 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

**Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

**Other information**

The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

**Matters on which we are required to report by exception**

We have nothing to report in respect of the following matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

- the information given in the Report of the Trustees is inconsistent in any material respect with the financial statements; or
- the charitable company has not kept adequate accounting records; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.



**Report of the Independent Auditors to the Trustees of  
The Urology Foundation (Registered number: 06817868)**

**Responsibilities of trustees**

As explained more fully in the Statement of Trustees' Responsibilities, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.





**Report of the Independent Auditors to the Trustees of  
The Urology Foundation (Registered number: 06817868)**

**Our responsibilities for the audit of the financial statements**

We have been appointed as auditors under Section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Extent to which the audit was considered capable of detecting irregularities, including fraud

We identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and then design and perform audit procedures responsive to those risks, including obtaining audit evidence that is sufficient and appropriate to provide a basis for our opinion.

Identifying and assessing potential risks related to irregularities

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, we considered the following:

- The nature of the charitable sector, control environment and performance including the design of the organisation's remuneration policies;
- Any matters we identified, having obtained and reviewed the organisation's documentation of their policies and procedures relating to:
  - o Identifying, evaluating and complying with laws and regulations and whether they were aware of any instances of non-compliance;
  - o Detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected or alleged fraud;
  - o The internal controls established to mitigate risks of fraud or non-compliance with laws and regulations;
  - o The matters discussed among the audit engagement team regarding how and where fraud might occur in the financial statements and any potential indicators of fraud.

As a result of these procedures, we considered the opportunities and incentives that may exist within the organisation for fraud and identified the greatest potential for fraud in the areas of management override of controls, going concern, income recognition, and the appropriateness of expenditure.

We also obtained an understanding of the legal and regulatory framework that the organisation operates in, focusing on provisions of those laws and regulations that had a direct effect on the determination of material amounts and disclosures in the financial statements.

Audit response to risks identified

Our procedures to respond to risks identified included the following:

- Enquiring of management, concerning actual and potential litigation and claims;
- Substantive testing to vouch source records to the financial statements;
- Performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud;



**Report of the Independent Auditors to the Trustees of  
The Urology Foundation (Registered number: 06817868)**

- Enquiring of management the internal controls in, evaluating each control for weakness and vouching to evidence of the control taking place;

- In addressing the risk of fraud through management override of controls, testing the appropriateness of journal entries and other adjustments; assessing whether the judgements made in making accounting estimates are indicative of a potential bias; and evaluating the business rationale of any significant transactions that are unusual or outside the normal course of business.

We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members, and remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at [www.frc.org.uk/auditorsresponsibilities](http://www.frc.org.uk/auditorsresponsibilities). This description forms part of our Report of the Independent Auditors.

**Use of our report**

This report is made solely to the charitable company's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charitable company's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

  
Matthew Dobbins (Sep 21, 2022 08:56 GMT+1)

Dunkley's  
Chartered Accountants  
Registered Auditors  
Eligible to act as an auditor in terms of Section 1212 of the Companies Act 2006  
Woodlands Grange  
Woodlands Lane  
Bradley Stoke  
Bristol  
BS32 4JY

Date: .....  
Sep 21, 2022





THE UROLOGY FOUNDATION

STATEMENT OF FINANCIAL ACTIVITIES  
for the year ended 31 December 2021

	Note	Unrestricted Funds £	Restricted Funds £	Total 2021 £	Total 2020 £
<b>INCOME</b>					
Donations and legacies	1	639,590	46,932	686,522	1,366,619
Other trading activities	2	83,389	-	83,389	64,920
Investments	3	41,020	-	41,020	653
<b>TOTAL INCOME</b>		<b>763,999</b>	<b>46,932</b>	<b>810,931</b>	<b>1,432,192</b>
<b>EXPENDITURE</b>					
<b>Raising Funds</b>					
Donations and legacies	4	42,022	4,665	46,687	51,864
Trading activities	5	21,262	2,358	23,620	22,612
Investment management costs		72	-	72	365
<b>Expenditure on Charitable activities</b>					
Raising Awareness	6	77,315	8,575	85,890	88,885
Grant making	7	614,398	128,530	742,928	1,068,277
Net (Gains) on investment assets	11	(377,255)	(472)	(377,727)	(360,241)
<b>TOTAL EXPENDITURE</b>		<b>377,814</b>	<b>143,656</b>	<b>521,470</b>	<b>871,761</b>
<b>NET INCOME/(EXPENDITURE)</b>		<b>386,185</b>	<b>(96,724)</b>	<b>289,461</b>	<b>560,431</b>
<b>RECONCILIATION OF FUNDS</b>					
Fund balances brought forward at 1 January 2021		1,675,542	482,881	2,158,423	1,597,992
Transfer between funds		35,389	(35,389)	-	-
<b>FUND BALANCES CARRIED FORWARD AT 31 DECEMBER 2021</b>		<b>2,097,116</b>	<b>350,768</b>	<b>2,447,884</b>	<b>2,158,423</b>

The net movement in funds for the year arises from the charity's continuing operations.

No separate statement of total changes in equity has been presented as all such gains and losses have been dealt with in the statement of financial activities.

*The notes on pages 29 to 39 form part of these accounts*



THE UROLOGY FOUNDATION

STATEMENT OF FINANCIAL ACTIVITIES

for the year ended 31 December 2020 (Full fund comparative)

	Note	Unrestricted Funds £	Restricted Funds £	Total 2020 £
<b>INCOME</b>				
Donations and legacies	1	515,235	851,384	1,366,619
Other trading activities	2	64,920	-	64,920
Investments	3	653	-	653
<b>TOTAL INCOME</b>		<b>580,808</b>	<b>851,384</b>	<b>1,432,192</b>
<b>EXPENDITURE</b>				
<b>Raising Funds</b>				
Donations and legacies	4	35,877	15,987	51,864
Trading activities	5	20,350	2,262	22,612
Investment management costs		365	-	365
<b>Expenditure on Charitable activities</b>				
Raising Awareness	6	79,994	8,890	88,884
Grant making	7	378,014	690,263	1,068,277
Net (Gains) on investment assets	11	(359,687)	(554)	(360,241)
<b>NET INCOME/(EXPENDITURE)</b>		<b>154,913</b>	<b>716,848</b>	<b>871,761</b>
<b>NET (EXPENDITURE)</b>		<b>425,895</b>	<b>134,536</b>	<b>560,431</b>
<b>RECONCILIATION OF FUNDS</b>				
Fund balances brought forward at 1 January 2020		1,249,647	348,345	1,597,992
Transfer between funds		-	-	-
<b>FUND BALANCES CARRIED FORWARD AT 31 DECEMBER 2020</b>		<b>1,675,542</b>	<b>482,881</b>	<b>2,158,423</b>

The net movement in funds for the year arises from the charity's continuing operations.

No separate statement of total changes in equity has been presented as all such gains and losses have been dealt with in the statement of financial activities.

*The notes on pages 29 to 39 form part of these accounts*





# THE UROLOGY FOUNDATION

## BALANCE SHEET as at 31 December 2021

Company Number 06817868

	Note	2021 £	2020 £
<b>FIXED ASSETS</b>			
Tangible assets	10	3,627	1,818
Investments	11	3,657,270	3,595,733
		<u>3,660,897</u>	<u>3,597,551</u>
<b>CURRENT ASSETS</b>			
Debtors	12	98,723	77,773
Cash at bank and in hand		238,420	217,109
		<u>337,143</u>	<u>294,882</u>
<b>LIABILITIES: amounts falling due within one year</b>	13	1,133,522	1,238,761
<b>NET CURRENT LIABILITIES</b>		<u>(796,379)</u>	<u>(943,879)</u>
<b>LIABILITIES: amounts falling due in more than one year</b>	13	416,634	495,249
<b>NET ASSETS</b>		<u>2,447,884</u>	<u>2,158,423</u>
<b>THE FUNDS OF THE CHARITY</b>			
<b>Restricted income funds</b>	15		
Robotic Surgery Training Fund		200,076	196,287
Prostate Cancer Research Fund		138,804	103,370
Bladder Cancer Fund		(31,425)	149,860
Travel Fellowship Fund		653	652
'EQUIP' Quality & Safety Pilot		-	30,889
Team Corbs - Testicular		2,158	1,823
Charles Reynolds		40,503	-
<b>Unrestricted income funds</b>	15		
General Fund		1,597,116	1,139,859
Designated Fund (Ralph Shackman)		-	35,683
Designated Fund (British Urology Foundation)		500,000	500,000
<b>TOTAL CHARITY FUNDS</b>	16	<u>2,447,884</u>	<u>2,158,423</u>

These financial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small charitable companies and with the Financial Reporting Standard 102.

The financial statements on pages 25 to 28 were approved by the trustees and authorised for issue on **Sep 20, 2022** and are signed on their behalf by

*Paul Fletcher*

Paul Fletcher (Sep 20, 2022 12:36 GMT+1)

Chairman

Paul Fletcher

Sep 20, 2022

*Angela Daniel*

Angela Daniel (Sep 20, 2022 13:07 GMT+1)

Treasurer

Angela Daniel

Sep 20, 2022

The notes on pages 29 to 39 form part of these accounts



THE UROLOGY FOUNDATION

STATEMENT OF CASHFLOWS  
as at 31 December 2021

	Note	2021 £	2020 £
<b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>	14		
Net cash used in operating activities		(333,651)	973,271
<b>Cash flows from investing activities:</b>			
Dividends and interest from investments		41,002	291
Management fees paid from investments		(72)	(365)
Purchase of equipment		(2,159)	-
Transfer from cash		-	(1,045,830)
Proceeds from sale of investments		852,452	1,162,282
Purchase of investments		(536,261)	(1,161,969)
<b>Net cash used in investing activities:</b>		<b>354,962</b>	<b>(1,045,591)</b>
Change in cash and cash equivalents in the reporting period		21,311	(72,320)
Cash equivalents at the beginning of the reporting period		217,109	289,429
Cash and cash equivalents at the end of the reporting period		238,420	217,109

*The notes on pages 29 to 39 form part of these accounts*





## THE UROLOGY FOUNDATION

Financial statements for the year ended 31 December 2021

### ACCOUNTING POLICIES

---

#### BASIS OF ACCOUNTING

The financial statements have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant notes to these accounts. The financial statements have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued on 1 January 2019 and Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and Charities Act 2011. The trust constitutes a public benefit entity as defined by FRS 102.

#### INCOME

Grants, donations and other similar types of voluntary income are brought into account when it is probable that they will be received, except that donated income is included gross of any attributable tax recoverable, where relevant. Donations given for specific purposes are treated as restricted income. Tax recoverable is recognised when claims are submitted to HM Revenue and Customs. Legacy gifts are recognised in the period in which the Charity becomes entitled to receive the income.

Income receivable from activities for generating funds and from investment income is accounted for on an accruals basis. Deferred income represents revenues collected but not earned as of 31 December 2021. This is primarily composed of income collected in advance of a fundraising event taking place and deferred until the charity is entitled to that income as and when the event takes place.

#### EXPENDITURE

Resources expended are allocated to the costs of generating funds or to the charity's principal activity where the costs can be identified as being directly related. All other costs are categorised as either support costs or governance costs, and are allocated in proportions based upon a suitable ratio applicable to the nature of the cost involved.

Grants payable are recognised in full in the period in which the approved offer is conveyed to the recipient. Grants are recognised and deferred where there is a long term commitment for the Charity. Where grants are recognised and conditions for staged grant payments are not met in subsequent years, an adjustment to grants payable will be made in the relevant accounting period. Expenditure includes irrecoverable VAT which is reported as part of the expenditure to which it relates.

#### TANGIBLE FIXED ASSETS

All tangible assets purchased that have an expected useful economic life that exceeds one year are capitalised and classified as fixed assets. Tangible fixed assets are stated at historical cost less depreciation. Depreciation is provided on all tangible fixed assets at rates calculated to write each asset down to its estimated residual value evenly over its expected useful life, as follows:

Office equipment	25% reducing balance
------------------	----------------------

#### OPERATING LEASES

Rentals under operating leases are charged to the Statement of financial activities on a straight line basis over the lease term.



## THE UROLOGY FOUNDATION

Financial statements for the year ended 31 December 2021

### ACCOUNTING POLICIES

---

#### INVESTMENTS

The charity's investments are included in the balance sheet at their market value. The gains or losses arising upon their annual revaluation are included in the statement of financial activities.

#### FUND ACCOUNTING

The general fund comprises the accumulated surpluses of unrestricted incoming resources over resources expended, which are available for use in the furtherance of the general objective of the charity.

Designated funds are a particular form of unrestricted funds consisting of amounts, which have been allocated or designated for specific purposes by the trustees. The use of designated funds remains at the discretion of the trustees.

Restricted funds are funds subject to specific conditions imposed by donors. The purpose and use of the restricted funds are set out in the notes to the accounts. Amounts unspent at the year end are carried forward in the balance sheet.

#### FOREIGN EXCHANGE

Receipts and payments which occur in foreign currencies are included in the accounts at the amount into which they are converted in sterling, using the exchange rate on the day in which the transaction occurs.

#### GOING CONCERN

The Trustees as Directors of the Charity believe that there are no material uncertainties that may cast significant doubt about the ability of the Charity to continue as a going concern, due to the significant unrestricted reserves as at 31st December and the forecast income expected in 2022. As we prepare this statement in early 2022, it is clear that the long tail of the COVID-19 pandemic, and its impact on the NHS workload, continues to have a bearing on the charity's operations, with applications for programmes such as fellowships and travel grants still low. It remains to be seen whether our events fundraising and income will be impacted by global issues such as the war in Ukraine and the current cost of living crisis, which may affect future budgets for research and training. The trustees believe, however, that given the level of available cash and reserves, the charity can continue as a going concern.

#### FINANCIAL INSTRUMENTS

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.





THE UROLOGY FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS  
for the year ended 31 December 2021

	Unrestricted funds £	Restricted funds £	2021 £	2020 £
<b>1. INCOME FROM DONATIONS AND LEGACIES</b>				
Grants received from charitable trusts and corporate sponsors	430,662	46,700	477,362	1,190,163
Donations	204,348	232	204,580	162,456
Legacies	4,580	-	4,580	14,000
	<u>639,590</u>	<u>46,932</u>	<u>686,522</u>	<u>1,366,619</u>
<b>2. INCOME FROM OTHER TRADING ACTIVITIES</b>				
Income from fundraising events	<u>83,389</u>	<u>-</u>	<u>83,389</u>	<u>64,920</u>
<b>3. INVESTMENT INCOME</b>				
Bank interest receivable on short term cash deposits	18	-	18	362
Income from investments listed on a recognised stock exchange:				
UK investments	41,002	-	41,002	291
Overseas investments	-	-	-	-
	<u>41,020</u>	<u>-</u>	<u>41,020</u>	<u>653</u>
<b>4. COSTS OF RAISING FUNDS VOLUNTARY INCOME</b>				
Direct costs	25,398	2,822	28,220	30,191
Support costs (see note 8)	16,624	1,843	18,467	21,673
	<u>42,022</u>	<u>4,665</u>	<u>46,687</u>	<u>51,864</u>



THE UROLOGY FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS  
for the year ended 31 December 2021

	Unrestricted funds £	Restricted funds £	2021 £	2020 £
<b>5. COSTS OF RAISING FUNDS TRADING ACTIVITIES</b>				
Costs of fundraising events	4,638	515	5,153	939
Support costs (see note 8)	16,624	1,843	18,467	21,673
	<u>21,262</u>	<u>2,358</u>	<u>23,620</u>	<u>22,612</u>
<b>6. COSTS OF RAISING AWARENESS</b>				
Costs of fundraising events	10,821	1,203	12,024	2,190
Support costs (see note 8)	66,494	7,372	73,866	86,695
	<u>77,315</u>	<u>8,575</u>	<u>85,890</u>	<u>88,885</u>
<b>7. GRANT MAKING</b>				
Research Scholarships awarded to 5 (2020: 3) individuals	295,939	(32,051)	263,888	120,950
Cancer biomarker / wearable sensor study	-	195,000	195,000	750,830
TUF Trials Unit	180,000	-	180,000	-
Small Research Projects awarded to 4 (2020: 3) teams	29,738	-	29,738	29,800
TUF Fulbright Research Fellowship Award	7,176	-	7,176	15,000
Urolink Fellowship	4,500	-	4,500	-
BAUN/TUF Nurse	2,156	-	2,156	6,200
Other direct costs	169	-	169	-
Keith Yeates medals awarded to 2 (2020: 1) individuals	(800)	-	(800)	2,000
V Arumham	(1,500)	-	(1,500)	-
BAUS	-	-	-	477
RSM Urology Section	-	-	-	6,000
COVID-surg Urology Study	-	-	-	10,000
Travel Grants	-	-	-	(1,289)
UTI Research	-	-	-	(22,667)
Movement in present value of grant accruals	(24,882)	(47,931)	(72,813)	(7,961)
	<u>492,496</u>	<u>115,018</u>	<u>607,514</u>	<u>909,340</u>
Support costs (see note 8)	121,902	13,512	135,414	158,937
	<u>614,398</u>	<u>128,530</u>	<u>742,928</u>	<u>1,068,277</u>



**NOTES TO THE FINANCIAL STATEMENTS**  
for the year ended 31 December 2021

**7. GRANT MAKING (Continued)**

The Charity's policy, in line with the Charities SORP 2019 is to recognise an expense and related liability for a research grant, at the point when the unconditional offer is conveyed to the recipient (see the accounting policy on page xx for further details). However, recipients do not always take up their research grants in full. Where this happens, in subsequent years, in order that the correct movement in the Charity's liability is recognised, the expense as shown in the Statement of Financial Activities may not reflect the level of grant giving in the current year. A reconciliation to assist with users' understanding of the grants awarded in the year, to the expense in the Statement of Financial Activities is provided below:

	Grants awarded in the year ended 31 December 2021	Effects of outstanding grant payments	Expense recognised in the accounts for the year ended 31 December 2021
Research Scholarships awarded to 5 (2020: 3) individuals	296,594	(32,706)	263,888
Small Research Projects awarded to 4 (2020: 3) teams	39,738	(10,000)	29,738
TUF Fulbright Research Fellowship Award	22,176	(15,000)	7,176
UTI Research	-	-	-
BAUS	-	-	-
RSM Urology Section	-	-	-
Keith Yeates medals awarded to 2 (2020: 1) individuals	4,000	(4,800)	(800)
Travel Grants	-	-	-
Educational Course	-	-	-
Cancer biomarker / wearable sensor study	195,000	-	195,000
BAUN/TUF Nurse	2,000	156	2,156
COVID-surg Urology Study	-	-	-
Urolink Fellowship	4,500	-	4,500
TUF Trials Unit	180,000	-	180,000
Other direct costs	-	169	169
V Arumham	-	(1,500)	(1,500)
Movement in present value of grant accruals	-	(72,813)	(72,813)
	<b>744,008</b>	<b>(136,494)</b>	<b>607,514</b>
Support costs (see note 8)	135,414	-	135,414
	<b>879,422</b>	<b>(136,494)</b>	<b>742,928</b>





NOTES TO THE FINANCIAL STATEMENTS  
for the year ended 31 December 2021

	Costs of generating voluntary income 7.5% £	Fundraising trading: Cost of goods sold 7.5% £	Awareness raising 30% £	Giving grants 55% £	2021 £	2020 £
<b>8. SUPPORT AND GOVERNANCE COSTS (UNRESTRICTED)</b>						
Staff costs (see note 9)	9,799	9,799	39,197	71,859	130,653	162,978
Other staff costs including recruitment	1,868	1,868	7,473	13,700	24,909	2,565
Committee and other staff welfare expenses	25	25	100	183	333	574
Other office costs	3,089	3,089	12,357	22,654	41,189	59,878
Audit fee	218	218	870	1,594	2,900	2,901
Accountancy and advisory services	980	980	3,920	7,186	13,066	15,192
Other costs	607	607	2,429	4,453	8,097	15,442
Depreciation-owned assets	37	37	149	273	496	546
	<u>16,624</u>	<u>16,624</u>	<u>66,494</u>	<u>121,902</u>	<u>221,644</u>	<u>260,076</u>

**8. SUPPORT AND GOVERNANCE COSTS (RESTRICTED)**

Staff costs (see note 9)	1,081	1,081	4,324	7,927	14,412	18,109
Other staff costs including recruitment	211	211	844	1,547	2,813	285
Committee and other staff welfare expenses	3	3	11	20	37	64
Other office costs	343	343	1,373	2,517	4,576	6,653
Audit fee	24	24	97	178	323	322
Accountancy and advisory services	109	109	436	799	1,453	1,688
Other costs	68	68	270	496	901	1,717
Depreciation-owned assets	4	4	17	30	55	64
	<u>1,843</u>	<u>1,843</u>	<u>7,372</u>	<u>13,512</u>	<u>24,570</u>	<u>28,902</u>



NOTES TO THE FINANCIAL STATEMENTS  
for the year ended 31 December 2021

		2021	2020
9.	STAFF COSTS	No.	No.
The average monthly number of persons employed by the charity (excluding trustees) during the period was, as follows:			
Office and administration		2.7	3.5
		£	£
Staff costs for the above persons:			
Staff	Wages and salaries	51,800	84,690
Staff	Social security costs	3,743	6,411
Key management personnel	Wages and salaries	82,339	82,338
Key management personnel	Social security costs	7,183	7,648
		145,065	181,087

One employee received total emoluments in excess of £60,000 per annum during the period ended 31 December 2021. The total emoluments of this employee during the year were in the following ranges:

	2021	2020
£70,000 - £80,000	No. 1	1

The Charity considers its key management personnel comprise the Chief Executive, with remuneration as noted above. In setting salary levels, The Urology Foundation follows the National Council for Voluntary Organisation's advice that a charity's pay policy should be to offer fair pay to attract and keep appropriately-qualified staff to lead, manage, support and/or deliver the charity's aims. It also conducts online research of charity salaries and uses surveys to benchmark levels of pay. The Urology Foundation does not automatically award its staff with annual salary increases, either incremental or cost of living.

No Director received any remuneration from the Company during the year (2020: £nil).

No trustee received any remuneration for services provided to the charity during the current or previous period. Trustees expenses reimbursed in respect of Trustee's meetings and travel for the year ended 31st December 2021 amounted to £0 paid to no Trustees (2020 £0 paid to no Trustees).

10. TANGIBLE ASSETS	Office Equipment £
Cost:	
1 January 2021	20,335
Additions	2,159
31 December 2021	22,494
Depreciation:	
1 January 2021	18,517
Charge for year	350
31 December 2021	18,867
Net book value:	
31 December 2021	3,627
31 December 2020	1,818



NOTES TO THE FINANCIAL STATEMENTS  
for the year ended 31 December 2021

		2021 £	2020 £
<b>11. INVESTMENTS</b>			
Investments listed on a recognised stock exchange at market value:			
1 January 2021		3,595,733	2,189,975
Transfers from cash		-	1,045,830
Additions at cost		536,261	1,161,969
Disposal proceeds		(852,452)	(1,162,282)
Realised (losses)/gains		124,555	(49,621)
Unrealised gains		253,173	409,862
31 December 2021		<u>3,657,270</u>	<u>3,595,733</u>
At the balance sheet date, the market value of the portfolio comprised:			
UK investments		3,657,270	3,595,733
		<u>3,657,270</u>	<u>3,595,733</u>
Fixed income securities		543,742	750,830
Equities		-	-
Multi-Asset & Hybrid Instruments		3,113,528	2,844,903
		<u>3,657,270</u>	<u>3,595,733</u>
At the balance sheet date, the historical cost of the investments was £2,938,371 (2020: £3,185,794). The following holdings had a value of >5% of the market value of the investments:			
<b>Name</b>	<b>Holding</b>	<b>Value £ 2021</b>	<b>Value £ 2020</b>
Rothschild & Co WM SICAV-SIF Exbury Fund GBP	116,874	3,113,528	2,844,903
Pentairs QIAIF PLC - Vanda Fund Shs -F- USD Shs	-	-	-
InstitutionalCash SeriesPLC - BlackRock ICS Sterling Liquidity Fur	543,715	543,742	750,830
<b>12. DEBTORS</b>		<b>2021 £</b>	<b>2020 £</b>
Amounts falling due within one year:			
Other debtors		3,017	2,761
Prepayments		21,450	19,574
Accrued Income		74,256	55,438
		<u>98,723</u>	<u>77,773</u>





THE UROLOGY FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS  
for the year ended 31 December 2021

13.	CREDITORS	2021 £	2020 £			
Amounts falling due within one year:						
Deferred income	80,628	34,778				
General accruals	11,270	10,895				
Grant accruals	1,041,624	1,193,088				
	<u>1,133,522</u>	<u>1,238,761</u>				
Deferred income b/fwd at 1 January 2021	34,778					
Amounts released in the year	(34,778)					
New amounts deferred in the year	80,628					
Deferred income c/fwd at 31 December 2021	<u>80,628</u>					
CREDITORS	2021 £	2020 £				
Amounts falling due in more than one year:						
Grant accruals	416,634	495,249				
	<u>416,634</u>	<u>495,249</u>				
14.	RECONCILIATION OF NET INCOME/(EXPENDITURE) TO NET CASHFLOW FROM OPERATING ACTIVITIES					
Net Income/(expenditure) for the reporting period per the statement of financial activities						
	289,461	560,431				
Adjustments for:						
Depreciation charges	350	606				
(Gains) on investments	(377,727)	(360,241)				
Dividends and interest from investments	(41,002)	(291)				
Management fees paid from investments	72	365				
(Increase)/Decrease in debtors	(20,950)	53,262				
(Decrease)/Increase in creditors	(183,855)	719,139				
Net cash used in operating activities	<u>(333,651)</u>	<u>973,271</u>				
15.	THE FUNDS OF THE CHARITY					
	1 January 2021 £	Transfer £	Income £	Expenditure £	Gains/(losses) on Investments £	31 December 2021 £
Restricted income funds:						
Robotic Surgery						
Training Fund	196,287	-	(94)	3,641	242	200,076
Prostate Cancer Research Fund	103,370	-	-	35,340	94	138,804
Bladder Cancer Fund	149,860	-	-	(181,360)	75	(31,425)
Travel Fellowship Fund	652	-	-	-	1	653
'EQUIP' Quality & Safety Pilot	30,889	(35,389)	6,194	(1,748)	54	-
Team Corbs - Testicular	1,823	-	332	-	3	2,158
Charles Reynolds	-	-	40,500	-	3	40,503
	<u>482,881</u>	<u>(35,389)</u>	<u>46,932</u>	<u>(144,128)</u>	<u>472</u>	<u>350,768</u>
Unrestricted income funds:						
General Fund	1,139,859	35,768	763,999	(719,765)	377,255	1,597,116
Designated Fund (R. Shackman)	35,683	(379)	-	(35,304)	-	-
Designated Fund (BUF)	500,000	-	-	-	-	500,000
	<u>2,158,423</u>	<u>-</u>	<u>810,931</u>	<u>(899,197)</u>	<u>377,727</u>	<u>2,447,884</u>



**NOTES TO THE FINANCIAL STATEMENTS**  
**for the year ended 31 December 2021**

---

**15. THE FUNDS OF THE CHARITY (Continued)**

- The trustees have designated the original 1995 start-up funding for the BUF of £500,000 as the trustees feel strongly that The Foundation should seek to maintain reserves sufficient to continue to fund its objectives on a long term basis.
- Ralph Shackman Trust - The Ralph Shackman Trust's aims were similar to TUF, being to advance the study of urology through grants and awards and funding clinical visits. In 2012 the Trust asked TUF to assist them in promoting and administering their clinical visit grants. In 2015 the Trust wound down and transferred its remaining assets to TUF. This included the responsibilities for administering the Keith Yeates Medal, an Award given to the Urology Trainee who receives the highest marks in the Intercollegiate Specialist Exams in Urology. This award comes with a prize of £2,000 for a TUF/Shackman travelling fellowship.
- The Robotic Surgery Training Fund was set up in 2009 following the receipt of restricted donation income from the British Urological Foundation and a generous private donation. The funds are mainly used to award grants towards robotically assisted surgery training, education, and research into robotic training techniques.
- Bladder cancer remains one of the most expensive cancers to treat and survival rates appear to have reached a plateau at 50%. In the UK, more than 10,000 new cases of bladder cancer are diagnosed every year. The Foundation is determined to improve the diagnosis, treatment and outcomes of people with bladder cancer and to allocate resources to vital research into the diagnosis and pathology of bladder cancer and to funding training and education to improve patient treatment and care. Through a generous donation from The Champniss Foundation, TUF has funded the iROC bladder cancer surgery trial, investigating the efficacy of Robot assisted radical cystectomy and intracorporeal urinary diversion compared with open radical cystectomy in patients with bladder cancer. The Champniss Foundation and the Champniss Charitable Trust are also funding a study into patient tracking post-surgery via fitness devices.
- Prostate Cancer Research - Thanks to the John Black Charitable Foundation (JBCF) TUF has been able to invest in a number of high profile research studies, such as the CLIMATE trial, which are ongoing. There were no new JBCF awards given in 2021.
- Education in Quality Improvement Programme (EQUIP) - The Urology Foundation is keen to deliver real improvements in patient care, while also developing urologists and equipping them to become leaders of the future. We supported the development of the EQUIP training programme, that equips urologists with the skills required to analyse current practise and to develop collaborative quality improvement work, and to share learning and best practices with their peers and urology departments regionally and nationally. This programme has now been incorporated into the urology curriculum and the anticipated benefits will be improved patient safety and care that will reflect a culture that fosters continuous improvement. We are grateful to the Schroder Foundation and a number of other funders for their generous support of the programme.
- The Foundation started working with former England and Lions rugby champion, Alex Corbisiero, to raise funds for research into testicular cancer, following Alex's diagnosis. A Just Giving page has been set up and the charity will continue to fundraise with Alex.



**16. ANALYSIS OF NET ASSETS BETWEEN FUNDS**

	Fixed Assets £	Net Assets/(Liabilities) £	Total £
<b>Restricted income funds:</b>			
Robotic Surgery Training Fund	200,076	-	200,076
Prostate Cancer Research Fund	982,367	(843,563)	138,804
Bladder Cancer Fund	149,934	(181,359)	(31,425)
Travel Fellowship Fund	1,123	(470)	653
Team Corbs - Testicular	-	2,158	2,158
Charles Reynolds	-	40,503	40,503
<b>Unrestricted income funds:</b>			
General Fund	1,827,397	(230,281)	1,597,116
Designated Fund (Ralph Shackman)	-	-	-
Designated Fund (British Urology Foundation)	500,000	-	500,000
<b>NET ASSETS</b>	<b>3,660,897</b>	<b>(1,213,013)</b>	<b>2,447,884</b>

**17. ULTIMATE CONTROLLING PARTY**

The Charity is controlled by the board of Trustees.

**18. COMMITMENTS UNDER OPERATING LEASES**

As at 31st December 2021, the Charity had annualised operating commitments under non-cancellable operating leases expiring as follows:

	2021 £	2020 £
Expiring within one year		
- Land and Buildings	28,700	49,200
- Others	1,566	3,132
	<u>30,266</u>	<u>52,332</u>
Expiring within two to five years		
- Land and Buildings	-	28,700
- Others	-	1,566
	<u>-</u>	<u>29,366</u>

**19. CONTINGENT ASSETS**

As at 31st December 2019, the Trustees were aware of a Legacy which is due to The Urology Foundation. The Legacy is the balance of the sale of a property, a 14% share of the estate was bequeathed to the Charity in 2013/2014. £9,000 was received in 2020 and a further £4,580 was expected and paid in 2022 and has been accrued into the 31st December 2021 accounts.

**20. RELATED PARTY TRANSACTIONS**

There were no related party transactions in the period under review or in the prior year.

